A federal district court in Brooklyn, New York, has held that state law tort claims involving a Class II medical device cleared for marketing by the FDA through the de novo process are not expressly preempted by federal law, even when the agency’s clearance of the device is accompanied by a set of special controls that the FDA said should be addressed by future devices of the ... Read More